BMS 777607

Drug Profile

BMS 777607

Alternative Names: ASLAN-002; BMS-777607; BMS-797669

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ASLAN Pharmaceuticals; Bristol-Myers Squibb
  • Class Aminopyridines; Antineoplastics; Dihydropyridines; Pyridones; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 05 Dec 2012 Aslan Pharmaceuticals initiates enrolment in a phase I trial for Solid tumours in Australia (NCT01721148)
  • 04 Nov 2011 Aslan Pharmaceuticals has acquired the exclusive rights to develop and commercialise BMS 777607 in China, Australia, Korea, Taiwan and selected other Asian countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top